Meeting
2019 ASCO Annual Meeting
A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced/recurrent endometrial cancer.
Authors
Raanan Alter
University of Chicago, Chicago, IL
Raanan Alter , Gini F. Fleming , Walter Michael Stadler , Akash Patnaik
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT03572478
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS2663)
DOI
10.1200/JCO.2019.37.15_suppl.TPS2663
Abstract #
TPS2663
Poster Bd #
297b
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer.
First Author: Akash Patnaik
Poster
2021 ASCO Annual Meeting
Complementary detection of genomic alterations in metastatic castration‑resistant prostate cancer (mCRPC) from CheckMate 9KD through analyses of tumor tissue and plasma DNA.
First Author: Mark Sausen
Poster
2023 ASCO Annual Meeting
A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.
First Author: Bradley Corr
Poster
2019 ASCO Annual Meeting
NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.
First Author: Helen Mackay